delivering clinical research to make patients, and the nhs, better haematological cancer research...
TRANSCRIPT
Delivering clinical research to make patients, and the NHS, better
Haematological Cancer Research Report
Site Specific Group MeetingTuesday 14th October 2014
Maxine TaylorSenior Research Delivery Manager
• Overview of network changes• Request for research lead• Overview of research activity• Discussion re new studies for the portfolio
2
CRN - West of England
• - Population 2.4 million• - Budget £13.2 million• - 7 Acute Trusts• - 2 Mental Health Trusts• - CCL Principal Treatment Centre• - Full team only since August 1st• - Small core support team based at
host in Bristol• - Not exactly mapping SSGs
BathBristolCheltenhamGloucesterWeston Super MareSwindon
Purpose
• Translation of national workstreams and objectives (HLOs and specialty specific) with strategic oversight of research activity within the geography of CRN - West of England in terms of:
– Portfolio• Balance, new studies, feasibility, industry trials
– Performance• Targets, support timely set up, support timely
recruitment– People
• Skill mix, flexibility, resources, training
4
Management Model
• Divisions 2 & 6
• Divisions 3 & 4
• Division 5
• Division 1
Maxine TaylorSenior RDM Workforce
Development
Martine CrossSenior RDM RM&G and
Industry Lead
Ruth AllenRDM
Business Intelligence lead
Chantal SunterRDM
PCPIE and Comms Lead
Mary PerkinsChief Operating Officer
The Clinical Team
Dr Steve Falk
Clinical Director
6 Divisional Clinical Leads
Prof Hugh Barr for Div 1
30 Specialty Leads
Sub Specialty Leads
Sue Taylor
Network Consultant Nurse
Clinical Research Teams
Imaging Adv. panel
Screening, Prevention &
Early Diagnosis
CTRad (Radiotherapy)
Psychosocial & Survivorship
Teenage &Young Adult
Palliative & Supportive Care
Biomarkers Adv. panel
Primary Care
Consumer Liaison Group
Breast CancerCSG
Lung CancerCSG Upper GI
CancerCSG
Colorectal CancerCSG
Kidney CancerCSG
Bladder CancerCSGTestis
CancerCSG
Gynae CancerCSG
PPI
Brain Tumours
CSGHead & Neck CSG
SarcomaCSG
MelanomaCSG
LymphomaCSG
Haematol.CSG Prostate
CancerCSG
Children’s Cancer &
Leukaemia
Division 1 Clinical Lead
•Brain cancer•H&N cancer •Lung cancer•Breast cancer•Sarcoma•Skin Cancer•Children/young people
•Upper GI cancer•Colorectal cancer•Urological cancer•Gynae cancer•Haem/lymphoma•Pall/Supportive & Psychosocial
13 LCRN Subspecialty Leads:
LCRN (x15)
Clin Director
LCRN Exec Board
COO
Division 1 RDM
Research Delivery Teams
Partnership Group Clin. Advisory Group
[ +/- other clinical roles]
NIHR CRN High Level Objectives
• Set up as fast as you can• Recruit as many and as fast as you can• All organisations• Commercial and non commercial• Specialty specific objectives
How important is cancer on our patch?
58
23
172120
34
67
WTE per division
Div 1Div 2Div 3Div 4Div 5 Div 6Generic
• Cancer incidence 9544• 242 recruiting studies• £2 million (16%)• Funding per incident case approx
£220• Funding per recruit £800• Exceeded both recruitment
targets for last 2 years• Largest non commercial portfolio• Benefit from continued good
national and international links
12
0
500
1000
1500
2000
2500
3000
3500
CRN: West of England Performance against target 14/15 (ytd)
Recruitment (YTD) Target Q1 14/15 Target 14 / 15
*
*Primary care target 9224
Haem onc recruitment ytd by Trust: Interventional and non-interventional studies
13
0
5
10
15
20
25
30
35
40
45
16 7 12 8 6 33 0 1
10
21
19
30
8
ObservationalInterventional
Haem onc recruitment ytd by Trust and study
14
0
5
10
15
20
25
30
9
20
10
5
0 0
4
01 1 1
0
32
1
25
3
01
35
13
12
8
3
12
8
4
108
9
4
Gloucestershire Hospitals NHS Founda-tion TrustGreat Western Hospitals NHS Founda-tion TrustNorth Bristol NHS TrustRoyal United Hospital Bath NHS TrustTauntonUniversity Hospitals Bristol NHS Founda-tion TrustWeston Area Health NHS TrustYeovil
Lymphoma recruitment ytd by Trust and study
15
0
0.5
1
1.5
2
2.5
3
3.5
CHEMO-T
EuroNet PHL-C1 Hodgkin's
NCRN069 ORCHARRD - Ofatumumab vs Rituximab followed by ASCT in DLBCL
NCRN568 - ARROVEN - brentuximab vedotin PASS
NSHLG - National Study of Hodgkin's Lymphoma Genetics
PACIFICO
ProT4 (Prophylactic Transfer of CD4 Lymphocytes)
R2W: Randomised phase 2 trial in Waldenstrom macroglobulinaemia
REMoDLB
Contact details
• http://csg.ncri.org.uk/portfolio-maps/
• http://www.crn.nihr.ac.uk/can-help/funders-academics/nihrcrn-portfolio/
16
17